The Alliance for Artificial Intelligence in Healthcare (AAIH)

Earlier this month the EU released the European Union Artificial Intelligence Act (The Act). #AAIHmembers Paul Howard, PhD, Senior Director of Amicus Therapeutics, Elaine H., Executive Director of the The Alliance for Artificial Intelligence in Healthcare (AAIH), Mustaqhusain Kazi Global Head of Informatics Strategy and Digital Innovation at Roche, Rafael Rosengarten Co-Founder and CEO of Genialis and James Zanewicz, JD, LLM, RTTP, Chief Business Officer at Tulane University School of Medicine, authored a response of behalf of #AAIH to the provisional agreement. This article provides valuable insights into several key aspects: the presence of bias in healthcare AI, the existing solutions addressed by the General Data Protection Regulation (GDPR), the dedication to ethically implementing AI, and the crucial role of human oversight in enhancing AI literacy. #aiinhealthcare #AI #regulation #GDPR #EU #theAct Read more in the full article here

Happy Friday! It’s time for our AAIH #FeatureFriday Spotlight, and today we’re excited to highlight Chandrasekhar Sharma from C5i! As a thought leader, Chandrasekhar Sharma is redefining the strategic landscape of the life sciences industry through transformative AI-driven leadership. Serving as a key executive at C5i, he has positioned organizations at the forefront of digital transformation, consistently driving enterprise-wide AI strategies that generate unprecedented business value. He is recognized for architecting comprehensive ecosystems that not only disrupt traditional operational models but also establish new paradigms of efficiency, productivity, and customer experience bringing into life compelling business models.   Chandrasekhar Sharma’s leadership is characterized by a forward-looking approach seamlessly integrating technological innovation with strategic business imperatives. As a sought-after strategic advisor to senior leadership teams , he translates complex AI capabilities into actionable, high-impact strategies that deliver measurable competitive advantages. His thought leadership extends beyond organizational boundaries, with influential contributions to strategic publications shaping AI's future in life sciences. The AAIH is proud to have Chandrasekhar Sharma and C5i as valued members of the organization!

AAIH End of Year Reflection: Celebrating Outstanding Advancements! AAIH member Genialis has made huge advances in 2024, foremost with the introduction of the Genialis™ Supermodel, the world’s first RNA-based foundation model of cancer biology. This large molecular model (LMM) drives biomarker discovery by mapping biological states across diverse patient samples, enabling precise prediction of drug responses, identification of resistance mechanisms, and development of combination strategies. Covering all of cancer biology, the Supermodel delivers predictive biomarkers for EVERY target, drug, and patient.    As a key proof of concept, Genialis launched Genialis™ krasID, the first biomarker panel both necessary and sufficient to predict tumor response and clinical benefit to KRAS-targeted therapeutics. After debuting at AACR in April, krasID was commercially launched in September at the RAS-Targeted Drug Development Summit. This first-in-class biomarker is already being evaluated by several top 20 pharmaceutical companies for its ability to transform patient stratification and guide drug development for KRAS-targeted therapies. These achievements are the result of Genialis’ advanced understanding of cancer biology, their ML models and deliberate efforts to aggregate globally representative patient data. Through collaborations with Sidra Medicine, Sapien Biosciences, PanCAN, and 4baseCare, to name a few, the company is building the world’s most ethnographically diverse cancer data set. These partnerships enhance the robustness and applicability of Genialis’ biomarkers, ensuring they are effective for all patients. By fueling the Supermodel with globally representative data, Genialis is advancing RNA biomarkers that support every aspect of oncology clinical development—for every target, drug, and patient. Rafael Rosengarten, Miha Stajdohar, Daniel Pointing, Gint Rudis, Aditya Pai

As part of our AAIH #YearinReview series, we’re excited to highlight another insightful publication: AI and Regulatory Innovation in Healthcare: Shaping the Future. At BIO 2024, the Alliance for Artificial Intelligence hosted a dynamic panel discussion on AI and regulatory challenges, moderated by Paul Howard, PhD, Senior Director at Amicus Therapeutics. The panel featured experts Christopher Escobedo Hart (Foley Hoag LLP), Mida Pezeshkian, PhD (STEMA_cg), Brandon Rice (Weave), and Alex Zhavoronkov (Insilico Medicine), who shared diverse perspectives on the intersection of AI and regulation. Key topics included: data privacy, best practices for training, testing, and validating machine learning models (including Generative AI) based on representative datasets, and how to grapple with challenges due to missing data, data bias, and hallucinations. This rich discussion provided valuable insights into navigating the evolving landscape of AI in healthcare. Check out the full article below for key takeaways and further details! https://lnkd.in/e6kza8P3

This weeks AAIH #MemberMonday feature is Envisagenics! Envisagenics uses Artificial Intelligence and High Performance Cloud Computing to analyze patients’ RNA sequencing data to develop therapeutics for treatment of cancer and neurodegenerative diseases, such as breast cancer, leukemia and ALS. Envisagenics’ SpliceCore® software platform leverages RNA sequencing data and AI/ML algorithms to identify, test and validate drug targets with greater speed and precision than traditional methods. To learn more about Envisagenics, visit https://lnkd.in/gQdwzPmz

AAIH End of Year Reflection: Honoring Exceptional Achievements! As we continue our End of Year Reflection, today the AAIH is excited to highlight yet another incredible achievement from our talented member Imagene! Imagene has launched CanvOI, a state-of-the-art Oncology Intelligence (OI) foundation model designed to decode cancer from biopsy images and facilitate innovative research and development in the digital pathology and oncology space. The model was developed in partnership with Oracle and Ellison Medical Intetute. CanvOI delivers a robust vision data backbone for the development of downstream applications in oncology research, including predicting treatment responses, discovering biomarkers, assessing disease prognosis, and identifying pathological features with state-of-the-art results, outperforming leading foundation models built for digital pathology. CanvOI is the cornerstone of Imagene’s new OI Suite, a platform that supports researchers and diagnostics developers to explore a wide range of questions to conduct in-depth research independently, alleviating the need for AI expertise and extensive data acquisition. OI Suite enables rapid discoveries while delivering the highest standards of data privacy and security. To read and learn more, visit the links below! CanvOI scientific paper: https://lnkd.in/exThg3WK CanvOI formal announcment with Oracle: https://lnkd.in/e8Aua7n6

AAIH End of Year Reflection: Celebrating Remarkable Achievements! As we continue to reflect on the incredible progress and milestones of 2024, the AAIH is thrilled to highlight the achievements and advancements of our outstanding members. Today, we are excited to showcase Epikast! At its core, Epikast is a people-first business, partnering with biopharma companies to enhance engagement with their most vital stakeholders: patients, physicians, partners and caregivers. They offer a range of solutions, including virtual Medical Science Liaisons (MSLs), virtual reps, and staffed patient call centers, all powered by extremely well qualified professionals such as PhDs, MDs, nurses, and pharmacists. While Epikast’s foundation is centered on human interactions, AI plays a significant role in elevating the impact of their business model. In 2024, Epikast has made significant advancements on the AI front, for example: 1. Custom AI Models Epikast developed proprietary AI systems that evaluate & synthesize copious amounts of content, enabling their teams to address the most complex scientific questions with confidence and precision. This ensures physicians receive well-informed, evidence-based responses, deepening trust and developing meaningful dialogue. 2. Specialized Large Language Models (LLMs) Epikast trained their own Large Language Models to analyze and extract actionable commercial content from every interaction they have with patients and HCPs on behalf of their clients. These insights empower their biopharma customers to refine their strategies and broaden market impact. By combining human expertise and cutting-edge AI capabilities, Epikast is proud to deliver a unique, scalable model that drives exceptional results for their clients while maintaining a human touch. At Epikast, they have pushed the boundaries of what is possible…and they are just getting started! The AAIH is incredibly proud to have Epikast as part of our community! Here's to more success and groundbreaking work in the years to come. Vangelis Vergetis Tara Goodman, M.P.H. Lynn Kasper

This weeks #WhatsupWednesday features DeciBio and their November AI newsletter! This newsletter provided several updates including: AI in Drug Discovery, AI in Diagnostics, and AI in Healthcare! Be sure to check it out below!

As part of our #YearinReview series, we are excited to highlight another outstanding publication from the AAIH: FDA's Collaborative Approach to Promoting Responsible AI in Medical Products. This publication was a collaborative effort with contributions from Hin Au, Esther W.B. Bleicher, Meredith Brown-Tuttle, RAC, FRAPS, Elaine H., Paul Howard, PhD, Rafael Rosengarten, Eva F. Yin, PhD, MPH, JD, Chandrasekhar Sharma, Alex Yue, and James Zanewicz, JD, LLM, RTTP. Throughout this publication, four key recommended areas of focus are outlined: 1.     Fostering collaboration to safeguard public health 2.     Advancing regulatory approaches that support innovation 3.     Promoting standards, guidelines, best practices, and tools 4.     Supporting research related to evaluating and monitoring AI performance This article underscores the transformative potential of AI in healthcare but also highlights the crucial steps needed to ensure we safely harness this potential. This is one of the key missions of the Alliance for AI in Healthcare. To read to full article, visit: https://lnkd.in/e6DShwht

This weeks AAIH #MemberMonday is Wilson Sonsini Goodrich & Rosati! Wilson Sonsini is a trusted advisor to trailblazers in the life sciences industry. Their mission is to facilitate the success of companies shaping the future of healthcare, and to help them navigate the complex legal landscape as AI and other new emerging technologies continue to evolve. To learn more about Wilson Sonsini, visit https://www.wsgr.com/en/